ESTRO 36 Abstract Book

637 / 1096

S621 ESTRO 36
_______________________________________________________________________________________________
EP-1140 Dosimetric comparison between Helical
Tomotherapy and IMRT for Bilateral Breast Cancer
M.H. Wang1
1 Shuang Ho Hospital, Department of Radiation Oncology,
Taipei, Taiwan
Purpose or Objective
This study aimed to compare treatment between
Tomotherapy and IMRT for bilateral breast cancer.
Material and Methods
We selected 10 patients of breast cancer who were
performed partial mastectomy for study. All patient were
early stage breast cancer pT1~T2. A total dose of 5040cGy
was delivered for definitive breast irradiation of IMRT and
Tomotherapy for each patient in treatment planning
system. In this study, we analyzed comparable treatment
of IMRT vs Tomotherapy for bilateral breast. Bilateral
whole breast dose coverage, Conformity index,
Homogeneity index and dose volume constraints of normal
tissue (Right and Left lung, Heart) were analyzed.
Results
Tomotherapy was better than IMRT for significant
improvements in reducing the volume of normal tissue. In
volume of heart in V20 (Tomo:1.543% versus IMRT: 2.955%;
p=0.023) and in lung volume achieving lower mean lung
dose (MLD) (Rt lung mean dose: Tomo: 6.388 Gy versus
IMRT: 8.828Gy; p = 0.017; Lt lung mean dose Tomo: 6.24
Gy versus IMRT: 7.71Gy; p = 0.013). The conformity indices
(V95%/V PTV) of right and left breast were (1.08 +/- 0.01) &
(1.07 +/- 0.02) in Tomo and (1.07 +/-0.02) & (1.08 +/-
0.01) in IMRT. For homogeneity indices, Tomo were (1.36
+/- 0.08) & (1.53+/- 0.46) and IMRT was (1.65 +/- 0.44) &
(1.51 +/- 0.26) in right and left breast.
Conclusion
Tomotherapy provided significant reduction in heart’s
dose volume and mean lung dose.
EP-1141 Acute and late toxicity of IORT during BCS
followed by whole breast radiotherapy (WBI).
B. Urbanski1, A. Roszak Andrzej1, K. Bratos1, P. Milecki2,
A. Karczewska-Dzionk3, M. Litoborski4, S. Adamczyk5
1 Greater Poland Cancer Centre, Radiotherapy and
Gynecological Oncology, Poznan, Poland
2 Greater Poland Cancer Centre, Radiotherapy Ward I,
Poznan, Poland
4 Candela, Candela, Warsaw, Poland
5 Intra Op, Intra Op, Sunnyvale, USA
Purpose/Objective:
The aim of the study was to report acute and late toxicity
of intraoperative radiotherapy (IORT) given as a boost
during breast conserving surgery (BCS) followed by
adjuvant whole breast radiotherapy (WBRT).Material and
Methods
Between 2008 and 2011 in 150 breast cancers patients
treated in Greater Poland Cancer Centre. Intraoperative
radiotherapy as a tumor bed boost was applied using
mobile electron accelerator Mobetron 1000 (IntraOp
Medical, Inc.). IORT boost (10 Gy) was followed by 50 Gy
whole-breast external beam radiotherapy (EBRT).
Chemotherapy, if indicated, was given before EBRT. The
observation period was 1,5-5,5 years.
The data was assessed by CTCAE ver. 3.0 scale 1 month
and 6 months after RT. The statistical analysis was
performed with Maentel-Haenszel test. Late toxicity was
analyzed with LENT-SOMA scale 1 year after RT.
Results
Tab 1. Acute toxicity data set.
There was only grade I and II acute toxicity reactions.
There was no statistical significance differences between
(Mantel-Haenszel test) percentage of patients with acute
reaction in 1 month and 6 months after RT.
Tab 2. Late toxicity data set.
The late toxicity occurred in 82 patients (55%). The main
side effect of treatment was fibrosis, which has occurred
in 60 patients (73.1%) from 82 in general with late
radiation induced reactions. There was grade I and II
predominance. Grade III occurred in 5 patients (skin
retraction).
Conclusion
Intraoperative radiotherapy is proved to be safe, well
tolerable and perspective treatment procedure in breast
cancer treatment.
EP-1142 EORTC QLQ C-30 scores evolution in stage I-III
breast cancer patients during sequential treatment
A. Vila1, J. Perez de Olaguer 1, P. Gallego1, G. Carrera1,
A. Pedro1
1Platón Hospital, Oncology and Radiation therapy,
Barcelona, Spain
Purpose or Objective
To analyse the quality of life in stage I-III breast cancer
patients under systemic treatment versus in adjuvant
radiotherapy respect a control group, to observe and to
assess priorities regarding quality of life
Material and Methods
Between May and July of 2014, n: 90 EORTC QLQ C-30
global tests were retrospectively observed in 48 women
divided in 3 groups: A) Sixteen breast cancer patients
under systemic treatment (following adjuvant
chemotherapy or hormonal treatment). B) Sixteen breast
cancer patients following radiotherapy were scored at the
beginning, during radiotherapy and when radiotherapy
courses just ended. C) Sixteen women, hospital workers,
without cancer control group, which two were finally
refused because they had symptoms of chronic fatigue
Results
Women mean ages were 63.5 years old (A), 60.5 years old
(B) and 41 years old in group C, respectively.
Among those 32 breast cancer patient (n: 76 tests), 6 (19%)
were submitted to mastectomy and 26 (81%) to
conservative surgery, with 5 of them that had been
treated with neo - adjuvant chemotherapy. Breast cancer
(TNM) stage was I, II or III in 50%, 37.5% and 12.5%,
respectively.
Asthenia was the main symptom in all cases being low in
control group. However, asthenia was considerable or
severe in the 56% of cases in the systemic treatment group
and 27.5% in radiotherapy group. Asthenia increases a 6%